RA responds to TNF and IL-17A inhibitors; Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing spondylitis respond to TNF and IL-23 inhibitors; atopic dermatitis responds to IL-4 and IL-13 inhibitors [86]. This evidence concerns the gene TNF and ulcerative colitis.